Blood brain barrier-serotonin dopamine-Blood brain barrier

The argument is simply, there are non-MD labs out there trying to promote the idea the serotonin, dopamine, norepinephrine, and epinephrine do not cross the blood brain barrier. In reviewing the literature the facts read the facts read them self, serotonin, dopamine, norepinephrine, and epinephrine do not cross the blood brain barrier, this has been know in science for years. At the left are a few articles discussing this.

Serotonin Blood Brain Barrier

Dopamine Blood Brain Barrier

Norepinephrine Blood Brain Barrier

Epinephrine Blood Brain Barrier

organic cation transporter neurotransmitter optimization

BLOOD BRAIN BARRIER

NeuroResearch Clinics relies exclusively on DBS Labs for urinary serotonin and dopamine organic cation transporter neurotransmitter optimization in natural treatment of disease. DBS Labs is directed by Tom Uncini, MD hospital based pathologist who is dual board certified in laboratory medicine. Dr. Uncini is the medical director of two hospital labs, University of Minnesota Medical Center Mesabi in Hibbing, MN and Cook Hospital in Cook, MN. Dr. Uncini is also on the faculty of the University of Minnesota Medical School. The urinary organic cation transporter neurotransmitter optimization produced by DBS Labs is of hospital caliber. Between Dr. Uncini and his lab manager there are over 50 years of hospital based laboratory experience.

The experience and credentials of the people running DBS Labs stand in stark contrast to the other labs out there attempting to do urinary organic cation transporter neurotransmitter optimization. Other laboratories have no hospital based board certified laboratory medicine pathologist running the lab, no license to practice medicine, no hospital privilege affiliation, no clinic, no patients, and have never treated one patient in clinic. Yet some are holding out that they have the expertise to tell doctors how to treat their patients when the urinary organic cation transporter neurotransmitter optimization results are reported back to the doctor. This may explain why the testing results of these labs do not correlate when the same sample is run on split sample testing by DBS Labs and the non-MD lab. These non-MD labs are the labs that are recommending and inducing licensed medical doctors to get "baseline urinary organic cation transporter neurotransmitter optimization" prior to treatment even though there is no correlation between testing prior to and once taking amino acid precursors

Blood Brain Barrier

- organic cation transporter neurotransmitter optimization

- organic cation transporter neurotransmitter optimization-In depth

- organic cation transporter neurotransmitter optimization-Source of urinary neurotransmitters

- organic cation transporter neurotransmitter optimization-Blood brain barrier

- organic cation transporter neurotransmitter optimization-Collection time

- organic cation transporter neurotransmitter optimization-Quality control

- organic cation transporter neurotransmitter optimization-Quality assurance

- organic cation transporter neurotransmitter optimization-Reference ranges

- organic cation transporter neurotransmitter optimization-Flawed results

- organic cation transporter neurotransmitter optimization-Julia Ross

- organic cation transporter neurotransmitter optimization-Baseline testing

- organic cation transporter neurotransmitter optimization-3 phase dosing versus 3 phase response

The University of Minnesota Medical School organic cation transporter neurotransmitter optimization paper.

FROM PEER REVIEWED LITERATURE

The goal of treatment is to establish both urinary serotonin and dopamine levels in the phase 3 therapeutic range. To determine the phase of serotonin and dopamine with certainty requires two urinary neurotransmitter tests to be performed with the patient simultaneously taking a different amino acid dosing of dopamine and serotonin amino acid precursors on each test and comparing the results. Not all patients will need to have the urinary serotonin and dopamine levels in the phase 3 therapeutic range for relief of symptoms. In many cases, adjusting the amino acids so that the patient moves closer to the phase 3 therapeutic range of urinary serotonin and dopamine induces relief of symptoms. Then, no further amino acid adjustments or testing are needed unless disease symptoms return.

Ingrid Kohlstadt, MD Johns Hopkins, Hinz, M. Depression in I. Kohlstadt (ed.)

Food and Nutrients in Disease Management (CRC Press, 2009)

organic cation transporter neurotransmitter optimization-BLOOD BRAIN BARRIER

If you need a medical speaker for AMA Category I CME call NeuroResearch Clinics, Inc.

NeuroResearch Clinics, Inc. only deals with and provides information to licensed health care professionals.

Blood Brain Barrier

keyz keyb

Blood Brain Barrier